Cancer Genetics Inc. (CGIX) Sees Strong Trading Volume
Cancer Genetics Inc. (NASDAQ:CGIX) shares saw unusually-high trading volume on Monday . Approximately 118,290 shares were traded during mid-day trading, an increase of 44% from the previous session’s volume of 82,345 shares.The stock last traded at $2.08 and had previously closed at $2.07.
Separately, Zacks Investment Research raised Cancer Genetics from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Friday, April 22nd.
The firm has a 50 day moving average of $2.06 and a 200 day moving average of $2.39. The firm’s market cap is $28.40 million.
Cancer Genetics (NASDAQ:CGIX) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $6.95 million. The company’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.44) earnings per share. On average, equities research analysts forecast that Cancer Genetics Inc. will post ($1.26) earnings per share for the current fiscal year.
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.